首页> 美国卫生研究院文献>Scientific Reports >Nomogram for cirrhosis in patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis
【2h】

Nomogram for cirrhosis in patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis

机译:慢性乙型肝炎患者肝硬化的诺法图:一种针对个人肝硬化风险的简单自我评估量表

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this retrospective study was to establish a simple self-assessed scale for individual risk of cirrhosis in patients with chronic hepatitis B. A total of 1808 consecutive patients were enrolled and analyzed. According to the results of multivariate logistic regression analysis, a simple nomogram was calculated for cirrhosis. The area under receiver operating characteristic curves (AUROCs) were calculated to compare the diagnostic accuracy of nomogram with aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the four factors (FIB-4), and S index. The AUROCs of nomogram for cirrhosis were 0.807 (adjusted AUROC 0.876) in model group and 0.794 (adjusted AUROC0.866) in validation group. DeLong’s test and Brier Score further demonstrated that nomogram was superior to APRI, FIB-4 and S index in both model group and validation group. The patients with nomogram <0.07 could be defined as low risk group with cirrhosis prevalence lower than 4.3% (17/397). The patients with nomogram >0.52 could be defined as high risk group with cirrhosis prevalence higher than 73.0% (119/163). In conclusion, as a self-assessed style, simple, non-invasive, economical, convenient, and repeatable scale, nomogram is suitable to serve as a massive health screening tool for cirrhosis in CHB patients and further external validation is needed.
机译:这项回顾性研究的目的是建立一种针对慢性乙型肝炎患者个人肝硬化风险的简单自我评估量表。总共入选并分析了1808名连续患者。根据多元逻辑回归分析的结果,计算出简单的列线图用于肝硬化。计算接收器工作特征曲线(AUROC)下的面积,以比较诺模图与天冬氨酸转氨酶与血小板的比率指数(APRI),基于四个因素的纤维化指数(FIB-4)和S指数的诊断准确性。肝硬化组的诺模图AUROCs为0.807(校正后的AUROC 0.876),验证组为0.794(校正后的AUROC0.866)。 DeLong的测试和Brier Score进一步证明,在模型组和验证组中,列线图均优于APRI,FIB-4和S指数。 nomogram <0.07的患者可被定义为肝硬化患病率低于4.3%的低风险组(17/397)。列线图> 0.52的患者可被定义为肝硬化患病率高于73.0%(119/163)的高危人群。总之,作为一种自我评估的方式,简单,无创,经济,方便和可重复的量表,列线图适合用作CHB患者肝硬化的大规模健康筛查工具,需要进一步的外部验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号